Stada Arzneimittel AG’s private equity owners have selected bookrunners for a potential initial public offering of the ...

The new 100,000 sqm facility required an investment of around $75m. It has an annual production capacity of 150 million packs ...

STADA opens new production site & supply-chain hub in Turda, Romania with an investment of US$ 75 million: Bad Vilbel, ...

Partners Group Holding AG has selected banks for a potential initial public offering of Ammega Group BV as the private equity ...

Stada Arzneimittel AG’s private equity owners have expanded the lineup to help lead a potential initial public offering of the German generic drugmaker, according to people familiar with the matter.

Stada Arzneimittel AG was founded in 1895 and operates in Bad Vilbel, Germany. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100).

under its new partnership with STADA Arzneimittel AG. This marks the first product launched through the collaboration with ...

Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

STADA Arzneimittel AG and Dr. Reddy’s Laboratories SA, have entered into agreements with Alvotech for the commercialization of AVT03, each partner with semi-exclusive commercial rights in Europe ...

Herbal Medicinal Products Market. The global herbal medicinal products market is experiencing significant growth, with total ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...